Stock analysts at StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV – Get Free Report) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
MediciNova Price Performance
NASDAQ:MNOV opened at $1.33 on Friday. The company has a fifty day simple moving average of $1.39 and a two-hundred day simple moving average of $1.44. The company has a market cap of $65.24 million, a price-to-earnings ratio of -7.82 and a beta of 0.70. MediciNova has a 52 week low of $1.26 and a 52 week high of $2.66.
MediciNova (NASDAQ:MNOV – Get Free Report) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). On average, analysts expect that MediciNova will post -0.23 EPS for the current year.
Institutional Investors Weigh In On MediciNova
MediciNova Company Profile
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Further Reading
- Five stocks we like better than MediciNova
- What is a Bond Market Holiday? How to Invest and Trade
- Buffett Bails on BYD: What It Means for the Future of EV Stocks
- How Can Investors Benefit From After-Hours Trading
- Domino’s vs. Papa John’s: Stock Showdown of Pizza Giants
- What is a buyback in stocks? A comprehensive guide for investors
- Williams-Sonoma Makes Stock More Accessible with a Stock Split
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.